Abstract
Disturbed metabolism of glycosaminoglycans (GAGs) has been proposed to play an important role in the pathogenesis of late diabetic complications. The effect of diabetic complications and metabolic control on both total serum GAGs content and the serum activity of lysosomal glycosidases (N-acetyl-β-D-glucosaminidase, α-L-fucosidase, β-D-galactosidase, and α-D-mannosidase) contributing to GAGs degradation, was investigated in 48 patients with type 2 diabetes mellitus. The activity of β-D-glucosidase and acid phosphatase, the lysosomal enzymes unrelated to GAGs metabolism, was determined for comparison. The elevated serum total GAG concentration in diabetic patients was strongly and positively influenced by poor metabolic compensation of diabetes and the presence of vascular complications. A similar tendency has been shown in regard to the activity of enzymes involved in GAG degradation, especially N-acetyl-β-D-glucosaminidase, α-L-fucosidase and β-D-galactosidase. Furthermore, the total serum GAG concentrations, as well as the activity of lysosomal enzymes involved in the extracellular matrix degradation, closely followed metabolic compensation, regardless of diabetic vascular complications. Thus, we suggest that increased values of the investigated parameters may indicate the degree of endothelial cell dysfunction and may be useful to predict the development of diabetic vascular pathology.
References
1. Selleck SB. Proteoglycans and pattern formation. Sugar biochemistry meets developmental genetics. Trends Genet 2000; 16: 206–12. 10.1016/S0168-9525(00)01997-1Search in Google Scholar
2. Olczyk K, Głowacki A, Koźma EM. Non-insulin-dependent diabetes mellitus-associated changes in serum glycosaminoglycans. Pathophysiology 1997; 4: 121–9. 10.1016/S0928-4680(97)00170-3Search in Google Scholar
3. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998; 67: 609–52. 10.1146/annurev.biochem.67.1.609Search in Google Scholar PubMed
4. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51: 3063–8. 10.2337/diabetes.51.10.3063Search in Google Scholar PubMed
5. Kresse H, Glösl J. Glycosaminoglycan degradation. Adv Enzymol 1987; 60: 217–311. 10.1002/9780470123065.ch4Search in Google Scholar PubMed
6. Fransson L-A, Belting M, Edgren G, Jönsson M, Mani K, Schmidtchen A, et al. Degradation of reprocessing of heparan sulphate in recycling glypican (heparan sulphate proteoglycan). Trends Glycosci Glycotechnol 1998; 10: 81–94. 10.4052/tigg.10.81Search in Google Scholar
7. Kaushal GP, Shah SV. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. J Clin Invest 2000; 105: 1335–7. 10.1172/JCI10078Search in Google Scholar PubMed PubMed Central
8. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17: 7–30. 10.1101/gad.1039703Search in Google Scholar PubMed
9. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetic complications. Diabetes Metab Res Rev 2001; 17: 412–21. 10.1002/dmrr.236Search in Google Scholar PubMed
10. Yokoyama H, Sato K, Okudaira M, Morita C, Takahashi C, Suzuki D, et al. Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Kidney Int 1999; 56: 650–8. 10.1046/j.1523-1755.1999.00591.xSearch in Google Scholar PubMed
11. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, et al. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathological changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000; 11: 2324–36. 10.1681/ASN.V11122324Search in Google Scholar
12. Parthasarathy N, Spiro RG. Effect of diabetes on the glycosaminoglycan component of human glomerular basement membrane. Diabetes 1982; 31: 738–41. 10.2337/diab.31.8.738Search in Google Scholar
13. Camejo G, Olsson U, Hurt-Camejo F, Baharamian N, Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atheroscler Suppl 2002; 3: 3–9. 10.1016/S1567-5688(01)00005-8Search in Google Scholar
14. Deckert T, Horowitz IM, Kofoed-Enevoldson A, Kjellen L, Deckert Mlykkelund C, Burcharth F. Possible genetic defects in regulation of patients with diabetic nephropathy. Diabetes 1991; 40: 764–70. 10.2337/diab.40.6.764Search in Google Scholar
15. Gambaro G, Škrha J, Cariello A. Glycosaminoglycan therapy for long-term diabetic complication? Diabetologia 1998; 41: 975–9. 10.1007/s001250051016Search in Google Scholar
16. Cadaval RA, Kohlman O, Michelacci YM. Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus. Glycobiology 2000; 10: 185–92. 10.1093/glycob/10.2.185Search in Google Scholar
17. Juretic D, Krajnovic VV, Lukac-Bajalo J. Altered distribution of urinary glycosaminoglycans in diabetic subjects. Acta Diabetol 2002; 39: 123–8. 10.1007/s005920200030Search in Google Scholar
18. Cariello A, Giungliano P, Dello Russo P, Pasariello N, Saccomanno F, Sgambato S. Glycosaminoglycans in human diabetes. Diabetes Metab 1983; 9: 32–4. Search in Google Scholar
19. Škrha J, Hilgertová J. Relationship of serum N-acetyl-β-glucosaminidase activity to oxidative stress in diabetes mellitus. Clin Chim Acta 1999; 282: 167–74. 10.1016/S0009-8981(99)00025-XSearch in Google Scholar
20. Barrett AJ, Heath MF. Lysosomal enzymes. In: Dingle JT, editor. Lysosomes: a laboratory handbook. Amsterdam: Elsevier/North Holland Biomedical Press, 1977:19–147. Search in Google Scholar
21. Volpi N, Cusmano M, Venturell T. Qualitative and quantitative studies of heparin and chondroiton sulfates innormal human plasma. Biochim Biophys Acta 1995; 1243: 49–58. 10.1016/0304-4165(94)00123-FSearch in Google Scholar
22. Blumenkrantz N, Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal Biochem 1973; 54: 484–9. 10.1016/0003-2697(73)90377-1Search in Google Scholar
23. Slim GC, Furneaux RH, Yorke SC. A procedure for analysis of glycosaminoglycan mixtures based on digestion by specific enzymes. Carbohydr Res 1994; 255: 285–93. 10.1016/S0008-6215(00)90985-6Search in Google Scholar
24. Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care 2000; 23: 234–40. 10.2337/diacare.23.2.234Search in Google Scholar
25. Schleicher E, Nerlich A. The role of hyperglycemia in the development of diabetic complications. Horm Metab Res 1996; 28: 367–73. 10.1055/s-2007-979817Search in Google Scholar
26. Cariello A. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetes complications. Diabetes Nutr Metab Clin Exp 1999; 12: 42–6. Search in Google Scholar
27. Weitgasser R, Schnoell F, Gappmayer B, Karting I. Prospective evaluation of urinary N-acetyl-β-D-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diabetes Care 1999; 22: 1882–6. 10.2337/diacare.22.11.1882Search in Google Scholar
28. Kościelniak-Kocurek E, Olczyk K, Kucharz EJ, Sonecki P, Zdenkowski W. Serum lysosomal glycosidase activity in patients with non-insulin-dependent diabetes mellitus: relationship to patient's metabolic control. Eur J Lab Med 1995; 3: 79–81. Search in Google Scholar
29. Hickman P, McCollum PT, Belch JF. Neutrophils may contribute to the morbidity and mortality of claudicants. Br J Surg 1994; 81: 790–8. 10.1002/bjs.1800810604Search in Google Scholar
30. Holdt-Lehmann B, Lehmann A, Korten G, Nagel HR, Nizze H, Schuff-Werner P. Diagnostic value of urinary alanine aminopeptidase and N-acetyl-β-D-glucosaminidase in comparison to α 1-microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin Chim Acta 2000; 29: 93–102. 10.1016/S0009-8981(00)00237-0Search in Google Scholar
31. Goi G, Bairati C, Segalini G, Burlina AB, Massaccessi L, Lovagnini A, et al. Alterations in the activity of several glycohydrolases in red blood cell membrane from type 2 diabetes mellitus patients. Metabolism 1999; 48: 817–21. 10.1016/S0026-0495(99)90211-1Search in Google Scholar
32. Chung TW, Yu JJ, Liu DZ. Reducing lipid peroxidation stress of erythrocyte membrane by α-tocopherol nicotinate plays an important role in improving blood rheological properties in type 2 diabetic patients with retinopathy. Diabetes Med 1998; 15: 380–5. 10.1002/(SICI)1096-9136(199805)15:5<380::AID-DIA592>3.0.CO;2-8Search in Google Scholar
33. Vanhoutte PM. Endothelium-derived free radicals: for worse and for better. J Clin Invest 2001; 107: 23–5. 10.1172/JCI11832Search in Google Scholar
34. Li H, Förstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190: 244–54. 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8Search in Google Scholar
35. Rellier N, Ruggiero-Lopez D, Lagarde M, Wiernsperger N. In vitro and in vivo alterations of enzymatic glycosylation in diabetes. Life Sci 1999; 64: 1571–83. 10.1016/S0024-3205(99)00094-6Search in Google Scholar
36. Boden G. Effect of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 121–4. 10.1055/s-2003-39781Search in Google Scholar PubMed
37. Lteif A, Mather K. Insulin resistance, metabolic syndrome and vascular diseases: update on mechanistic linkages. Can J Cardiol 2004; 20(Suppl B): 66B–76B. Search in Google Scholar
38. Chait A, Wight TN. Interaction of native and modified low-density lipoproteins with extracellular matrix. Curr Opin Lipidol 2000; 11: 457–63. 10.1097/00041433-200010000-00003Search in Google Scholar PubMed
39. Edwards IJ, Terry JG, Bell-Farrow AD, Cefalu WT. Improved glucose control decreases the interaction of plasma low-density lipoproteins with arterial proteoglycans. Metabolism 2002; 51: 1223–9. 10.1053/meta.2002.35177Search in Google Scholar PubMed
40. Ha TS, Duraisamy S, Faulkner JL, Kasinath BS. Regulation of glomerular endothelial cell proteoglycans by glucose. J Korean Med Sci 2004; 19: 245–52. 10.3346/jkms.2004.19.2.245Search in Google Scholar PubMed PubMed Central
41. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51: 3063–8. 10.2337/diabetes.51.10.3063Search in Google Scholar PubMed
42. McLennan SV, Martell SK, Yue DK. Effects of mesangium glycation on matrix metalloproteinase activities. Diabetes 2002; 51: 2612–8. 10.2337/diabetes.51.8.2612Search in Google Scholar PubMed
43. Sampson M, Davies I, Gavrilovic J, Sussams B, Brown J, Astley S, et al. Plasma matrix metalloproteinases, low density lipoprotein oxidisability and soluble adhesion molecules after a glucose load in type 2 diabetes. Cardiovasc Diabetol 2004; 3: 1–7. 10.1186/1475-2840-3-7Search in Google Scholar PubMed PubMed Central
44. Waters PJ, Flynn MD, Pennock ChA. Association between serum cholesterol and leukocyte lysosomal function. Ann Clin Biochem 1994; 31: 91. 10.1177/000456329403100117Search in Google Scholar PubMed
©2005 by Walter de Gruyter Berlin New York
